10 Stocks Stealing Market Spotlight

4. Nuvation Bio Inc. (NYSE:NUVB)

Nuvation rebounded by 12.05 percent on Wednesday to finish at $8.37 apiece following the stellar results of its phase 2 study for the efficacy of Safusidenib to treat of a type of brain tumor.

In an updated report on the same day, Nuvation Bio Inc. (NYSE:NUVB) said that the study met its primary endpoint, having demonstrated an objective response rate of 44.4 percent.

The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had no prior anticancer therapy except for resection or biopsy.

Side effects were also mostly mild to moderate and considered manageable.

Grade 3 or greater treatment-related adverse events occurred in five patients, while no Grade 5 events were reported.

“The results published in the journal of Neuro-Oncology demonstrate Safusidenib’s impressive response rate and prolonged progression-free survival that suggest the possibility to delay chemoradiation, potentially improving quality of life for patients,” said Nuvation Bio Inc. (NYSE:NUVB) President and CEO David Hung.